Breaks Categories: News

TuesdayOct 10, 2023 2:11 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Featured in Latest Episode of The Bell2Bell Podcast

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is featured in the latest Bell2Bell Podcast release. During the segment, podcast host Stuart Smith discusses the company with Clene president and CEO Rob Etherington, who explains Clene’s business model and provides an overview of recent developments, which provide hope to those affected by neurodegenerative conditions. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. “Clene spends every waking moment working on amyotrophic lateral sclerosis (‘ALS’), a devastating neurodegenerative condition,” said Clene president…

Continue Reading

TuesdayOct 10, 2023 1:54 pm

BioMedNewsBreaks – SOHM, Inc. (SHMN), UACI Collaborate to Advance ABBIE, a Groundbreaking Non-Viral Gene-Editing Technology

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced its entry into development collaboration with the University of Arizona Center for Innovation (“UACI”) to propel ABBIE, a non-viral gene-editing kit technology. UACI is a leading science and tech startup incubator that is directly connected to the University of Arizona, which is renowned for its contributions to the scientific community, ranking among the nation’s top 50 public universities by U.S. News & World Report. “We are delighted to assist SOHM and the development of ABBIE technology,” said UACI Executive…

Continue Reading

MondayOct 09, 2023 1:16 pm

BioMedNewsBreaks – IBN, BioMedWire to Provide Dedicated Media Coverage for Upcoming BioPharma Nexus Events

InvestorBrandNetwork (“IBN”), a dynamic communications organization, today announced its collaboration with BioPharma Nexus as an official media partner for its events this month. In addition, BioMedWire, a specialized communications platform dedicated to the life sciences sector and a key part of IBN’s Dynamic Brand Portfolio (“DBP”), will serve as an official media partner. For each of the events, IBN and BioMedWire will leverage advanced communications tools to provide dedicated coverage, including syndicated article dissemination throughout IBN’s extensive network of 5,000+ strategic partners, and offer updates on each event via IBN’s influential social media accounts. “It is a pleasure to work…

Continue Reading

MondayOct 09, 2023 12:34 pm

BioMedNewsBreaks – ROTH MKM’s Upcoming Conference to Feature Public Healthcare Companies Across Multiple Sub-Sectors

ROTH MKM, a full-service investment bank focused on serving growth companies and their investors, today announced plans to host its 2023 Healthcare Opportunities Conference in New York City on Oct. 12, 2023. The event will provide pre-qualified institutional investors and healthcare industry professionals the opportunity to interact closely with C-level executives of approximately 25 public companies selected by ROTH’s research analysts. With a multiple sub-sector focus, the conference will feature participating companies operating in biotechnology, pharmaceuticals, medical technologies and oncology therapeutics. “Meaningful conversations between companies and a wide spectrum of investors will be the main focus of our Healthcare Opportunities…

Continue Reading

FridayOct 06, 2023 11:39 am

BioMedNewsBreaks – Safety Shot Holdings Inc. (NASDAQ: SHOT) Announces Ring Sponsorship of Jorge Masvidal’s Gamebred Bareknuckle MMA

Safety Shot (NASDAQ: SHOT) today announced its entry into an agreement with mixed martial arts (“MMA”) superstar Jorge Masvidal’s Gamebred Bareknuckle MMA, the world’s first bareknuckle MMA promotion. Over the next year, Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity, will be the ring sponsor for 12 Gamebred Bareknuckle matches. “Jorge is a superstar in the MMA world with a huge following and his Gamebred Bareknuckle fight promotion has garnered a fast growing following with millions of people viewing matches online and live audiences cheering at…

Continue Reading

ThursdayOct 05, 2023 12:06 pm

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Reports Top-Line Results for Phase 2a Lomecel-B Clinical Trial

Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has released top-line results for its phase 2a trial of its investigational product Lomecel-B(TM). The study evaluated Lomecel-B for the treatment of mild Alzheimer’s disease. According to the report, the primary endpoint of safety was met across all study groups; in addition, the secondary endpoint of change from baseline to week 39 in Composite Alzheimer’s Disease Score (“CADS”) also demonstrated positive results. The report also noted that other doses demonstrated numerical…

Continue Reading

ThursdayOct 05, 2023 11:45 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $45.1M NINDS Grant to Support Expanded Access Protocol for CNM-Au8(R) in ALS

Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, was awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”), a division of the National Institutes of Health (“NIH”). The grant is to support an Expanded Access Protocol (“EAP”) for the company’s investigational drug, CNM-Au8(R), in amyotrophic lateral sclerosis (“ALS”). Also referred to as Compassionate Use, an EAP is an FDA-regulated pathway that allows people with a serious and life-threatening disease to access an investigational drug that is not yet approved by the U.S.…

Continue Reading

ThursdayOct 05, 2023 10:54 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into a definitive agreement with Celly Nutrition Corp. According to the announcement, the Oct. 4, 2023, agreement outlines the distribution of a portion of FSD Pharma's shareholdings of Celly Nu to certain securityholders of FSD Pharma. The company noted that it has scheduled a virtual meeting on Nov. 20, 2023, for FSD Pharma securityholders to consider and vote on a special resolution approving the agreement, or plan of arrangement. A prerevenue, early-stage research and development company,…

Continue Reading

WednesdayOct 04, 2023 2:59 pm

BioMedNewsBreaks – Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) Starts Trading After TradeUP Acquisition Corp., Estrella Biopharma Inc. Business Combination

Estrella Immunopharma (NASDAQ: ESLA, ESLAW), formerly known as TradeUP Acquisition Corp. (“UPTD”), has successful closed a business combination with Estrella Biopharma Inc. Estrella Biopharma is a preclinical-stage biopharmaceutical company focused on developing T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. According to the announcement, shares in the combined company — Estrella Immunopharma — began trading on Oct. 2, 2023; in addition, all remaining UPTD units will separate into their underlying components, consisting of one share of combined company's common stock and one-half of one warrant. The combined company brings together capital and a…

Continue Reading

WednesdayOct 04, 2023 2:12 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Dismissal of Motion, Wins $2.8 Million Award

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is reporting on the status of court action filed against it. The company announced that the Ontario Superior Court of Justice dismissed the motion to set aside an arbitration award to FSD Pharma; the motion was filed by Dr. Raza Bokhari, former FSD Pharma CEO of FSD Pharma and current CEO of Medicus Pharma Ltd. In addition, the company noted an earlier decision by the Honourable J. Douglas…

Continue Reading